nelfinavir has been researched along with Pancreatic Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V | 1 |
| Baine, MJ; Li, S; Li, X; Lin, C; Wu, G; Zhao, N | 1 |
| Cama, A; De Lellis, L; De Tursi, M; di Sebastiano, P; Florio, R; Lanuti, P; Marchisio, M; Massucci, A; Natoli, C; Tinari, N; Veschi, S | 1 |
| Bridgewater, J; Corrie, PG; Hawkins, M; Hurt, CN; Maughan, T; Mukherjee, S; O'Neill, E; Parsons, P; Patel, N; Radhakrishna, G; Sebag-Montefiore, D; Shaw, R; Strauss, VY; Tranter, B; Virdee, PS; Ward, E | 1 |
| Are, C; Grem, JL; Hahn, SM; Lazenby, A; Li, S; Lin, C; Ly, QP; Meza, JL; Sasson, A; Schwarz, JK; Verma, V; Wang, S | 1 |
| Evande, R; Grem, JL; Kattel, K; Mahato, RI; Mondal, G; Tan, C | 1 |
| Abraham, AG; Brunner, TB; Chu, KY; Durrant, L; Dutton, SJ; Eccles, C; Fokas, E; Hawkins, MA; Maughan, T; McKenna, WG; Mukherjee, S; O'Neill, E; Partridge, M; Patel, N; Wilson, JM; Woodward, M | 1 |
| Al-Assar, O; Bittner, MI; Brunner, TB; Lunardi, S; McKenna, WG; Stratford, MR | 1 |
| Brunner, TB; Cavallaro, A; Geiger, M; Grabenbauer, GG; Hohenberger, W; Lang-Welzenbach, M; Mantoni, TS; McKenna, WG; Sauer, R | 1 |
| Baerman, KM; Calvo, BF; Cox, AD; Kimple, RJ; Sartor, CI; Shields, JM; Tepper, JE; Vaseva, AV | 1 |
| Schutt, M; Xiang, Z; Zhou, JQ | 1 |
6 trial(s) available for nelfinavir and Pancreatic Neoplasms
| Article | Year |
|---|---|
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Magnetic Resonance Imaging; Male; Membrane Proteins; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Radiosurgery; Risk Assessment; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Nelfinavir; Neoplasms, Second Primary; Pancreatic Neoplasms; Radiation Dosage; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiosurgery | 2019 |
Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Nelfinavir; Pancreatic Neoplasms; Polymorphism, Restriction Fragment Length | 2015 |
ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.
Topics: Chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Pancreatic Neoplasms | 2016 |
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Pancreatic Neoplasms; Treatment Outcome | 2008 |
5 other study(ies) available for nelfinavir and Pancreatic Neoplasms
| Article | Year |
|---|---|
Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Middle Aged; Nelfinavir; Pancreatic Neoplasms; Radiosurgery; Treatment Outcome | 2019 |
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Erlotinib Hydrochloride; Humans; Nelfinavir; Nitroquinolines; Pancreatic Neoplasms | 2018 |
The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Female; HIV Protease Inhibitors; Mice; Mice, Nude; Nelfinavir; Pancreatic Neoplasms; Pancreatic Stellate Cells; Radiation-Sensitizing Agents | 2016 |
Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Female; Genes, ras; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mutation; Nelfinavir; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
[Impairment of IRS-2 signaling in rat insulinoma INS-1 cells by nelfinavir].
Topics: Animals; Cell Line, Tumor; Cell Survival; HIV Protease Inhibitors; Insulin Receptor Substrate Proteins; Insulinoma; Intracellular Signaling Peptides and Proteins; Islets of Langerhans; Nelfinavir; Pancreatic Neoplasms; Phosphoproteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction | 2004 |